Sunderkötter CH, Zelger B, Chen KR, Requena L, Piette W, Carlson JA, Dutz J, Lamprecht P, Mahr A, Aberer E, Werth VP, Wetter DA, Kawana S, Luqmani R, Frances C, Jorizzo J, Watts JR, Metze D, Caproni M, Alpsoy E, Callen JP, Fiorentino D, Merkel PA, Falk RJ, Jennette JC, et al.
Arthritis & rheumatology (Hoboken, N.J.). Date of publication 2018 Feb 1;volume 70(2):171-184.
1. Arthritis Rheumatol. 2018 Feb;70(2):171-184. doi: 10.1002/art.40375.
Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised
International Chapel Hill Consensus Conference Nomenclature of Vasculitides.
Sunderkötter CH(1), Zelger B(2), Chen KR(3), Requena L(4), Piette W(5), Carlson
JA(6), Dutz J(7), Lamprecht P(8), Mahr A(9), Aberer E(10), Werth VP(11), Wetter
DA(12), Kawana S(13), Luqmani R(14), Frances C(15), Jorizzo J(16), Watts JR(17),
Metze D(18), Caproni M(19), Alpsoy E(20), Callen JP(21), Fiorentino D(22), Merkel
PA(23), Falk RJ(24), Jennette JC(24).
Author information:
(1)University Hospital of Halle, Halle (Saale), Germany, and University of
Münster, Münster, Germany.
(2)Medical University Innsbruck, Innsbruck, Austria.
(3)Meguro Chen Dermatology Clinic, Tokyo, Japan.
(4)Universidad Autónoma, Madrid, Spain.
(5)John H. Stroger Jr. Hospital of Cook County and Rush University Medical
Center, Chicago, Illinois.
(6)Albany Medical College, Albany, New York.
(7)University of British Columbia, Vancouver, British Columbia, Canada.
(8)University of Lübeck, Lübeck, Germany.
(9)Hospital Saint-Louis, University Paris 7, Paris, France.
(10)Medical University of Graz, Graz, Austria.
(11)University of Pennsylvania and Corporal Michael J. Crescenz Veterans Affairs
Medical Center, Philadelphia, Pennsylvania.
(12)Mayo Clinic, Rochester, Minnesota.
(13)Nippon Medical School, Tokyo, Japan.
(14)University of Oxford, Oxford, UK.
(15)University Paris 6, Hôpital Tenon, Paris, France.
(16)Wake Forest School of Medicine, Winston Salem, North Carolina.
(17)Ipswich Hospital NHS Trust, Ipswich, UK, and Norwich Medical School,
University of East Anglia, Norwich, UK.
(18)University of Münster, Münster, Germany.
(19)University of Florence, Florence, Italy.
(20)Akdeniz University School of Medicine, Antalya, Turkey.
(21)University of Louisville, Louisville, Kentucky.
(22)Stanford University School of Medicine, Stanford, California.
(23)University of Pennsylvania, Philadelphia.
(24)University of North Carolina at Chapel Hill.
OBJECTIVE: To prepare a dermatologic addendum to the 2012 revised International
Chapel Hill Consensus Conference Nomenclature of Vasculitides (CHCC2012) to
address vasculitides affecting the skin (D-CHCC). The goal was to standardize the
names and definitions for cutaneous vasculitis.
METHODS: A nominal group technique with a facilitator was used to reach consensus
on the D-CHCC nomenclature, using multiple face-to-face meetings, e-mail
discussions, and teleconferences.
RESULTS: Standardized names, definitions, and descriptions were adopted for
cutaneous components of systemic vasculitides (e.g., cutaneous IgA vasculitis as
a component of systemic IgA vasculitis), skin-limited variants of systemic
vasculitides (e.g., skin-limited IgA vasculitis, drug-induced skin-limited
antineutrophil cytoplasmic antibody-associated vasculitis), and cutaneous
single-organ vasculitides that have no systemic counterparts (e.g., nodular
vasculitis). Cutaneous vasculitides that were not included in the CHCC2012
nomenclature were introduced.
CONCLUSION: Standardized names and definitions are a prerequisite for developing
validated classification and diagnostic criteria for cutaneous vasculitis.
Accurate identification of specifically defined variants of systemic and
skin-limited vasculitides requires knowledgeable integration of data from
clinical, laboratory, and pathologic studies. This proposed nomenclature of
vasculitides affecting the skin, the D-CHCC, provides a standard framework both
for clinicians and for investigators.
© 2017, American College of Rheumatology.
DOI: 10.1002/art.40375
PMID: 29136340 [Indexed for MEDLINE]
